Scripps Research Logo

Welcome to the Rosen Laboratory Website!


February 17, 2017

Ozanimod, discovered in the Rosen and Roberts laboratories, successfully treats Relapsing and Remitting Multiple Sclerosis in a 1346 patient phase 3 clinical trial. This disease-modifying treatment for MS  was discovered in the Scripps Research Institute Molecular Libraries Screening Center, funded by the NIH Common Fund grant #5U54 MH084512 to Hugh Rosen.

Read the press release by clicking here

August 29, 2016

The Rosen Lab's S1P3 mCherry mice are now being provided by The Jackson Laboratory, Catalog #028624. Click link for purchasing information:

S1P3 mCherry Mice at JAX

February 16, 2016


Science Signaling:Editor's Choice review of our recent PNAS publication:

J. R. Teijaro, S. Studer, N. Leaf, W. B. Kiosses, N. Nguyen, K. Matsuki, H. Negishi, T. Taniguchi, M. B. A. Oldstone, H. Rosen, S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-α autoamplification. Proc. Natl. Acad. Sci. U.S.A. 113, 1351–1356 (2016).


February 12, 2016


Bench-to-bedside in multiple sclerosis

Brilliant results for MS Patients! TSRI compound to be presented at ACTRIMS 2016 Forum, February 18-20th. After 72 weeks, 92% of patients remained on Ozanimod. Efficacy was outstanding with 63% of 1mg patients and 44% of 0.5mg patients showing No Evidence of Disease Activity. 


January 24, 2016 - LAB IN THE NEWS


More uses for MS drug, TSRI study suggests: Ozanimod, discovered at TSRI, may help with other autoimmune diseases CLICK HERE TO GO TO THE ARTICLE


January 22, 2016 - NEW PUBLICATION


Teijaro JR, Studer S, Leaf N, Kiosses WB, Nguyen N, Matsuki K, Negishi H, Taniguchi T, Oldstone MB, Rosen H. (2016) S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-α autoamplification. Proc Natl Acad Sci USA. 2016 Jan 19. pii: 201525356. [Epub ahead of print] PMID: 26787880  CLICK HERE TO READ IT NOW


January 20, 2016 - LAB IN THE NEWS


Fierce Biotech Research - Scripps team spots a new mechanism that drives Celgene's ozanimod, potential rivals  CLICK HERE TO GO TO THE ARTICLE


Additional Information on Ozanimod (RPC1063)

The Molecular Libraries and Imaging Program Continues to Pay Dividends

After Leaving the Common Fund

The Common Fund’s Molecular Libraries and Imaging (MLI) Program has made promising inroads in the development of new therapeutics for human disease. A compound initially discovered by the NIH Molecular Libraries Probe Production Center at The Scripps Research Institute (TSRI), which was a part of the MLI program, was a precursor to the drug candidate ozanimod; which is currently in two Phase III clinical trials –one for patients with relapsing multiple sclerosis and the other in patients with ulcerative colitis. Dr. Hugh Rosen, a professor at TSRI was a Center Principal Investigator...CLICK HERE TO READ ON

Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis


Comprehensive Center for Chemical Probe Discovery and Optimization at TSRI